Abstract / Summary
Background: Vatarakta, also known as Vatashonita, is described in Ayurveda as a disease arising from the pathological interaction of Vata and Rakta. Because classical descriptions include painful inflammatory manifestations of the extremities and joints, contemporary Ayurvedic literature frequently correlates Vatarakta with gout. Modern gout, however, is a crystal-deposition disease involving monosodium urate (MSU) crystals. Clinical resemblance between the two conditions does not necessarily establish diagnostic or pathophysiological equivalence. Objective: This review critically examines the relationship between Vatarakta and gout, identifies areas of meaningful overlap, clarifies the limitations of assuming equivalence, and proposes a multidomain framework for future validation research. Materials and Methods: A critical narrative review was conducted using classical Ayurvedic sources and contemporary literature on Vatarakta, gout, hyperuricemia, MSU crystal deposition, and crystal-induced arthropathies. Evidence was considered across Ayurvedic, clinical, biochemical, crystal-identification, and imaging domains, with particular attention to contemporary gout classification criteria and diagnostic recommendations. As this was a narrative review, formal meta-analysis and risk-of-bias assessment were not undertaken. Results: The reviewed literature indicates substantial phenotypic overlap between Vatarakta and gout, particularly in painful inflammatory manifestations of peripheral joints. However, hyperuricemia and non-specific joint inflammation are insufficient to establish gout. Identification of MSU crystals provides direct evidence of urate crystal deposition and is sufficient for classification under the 2015 ACR/EULAR criteria; in the absence of crystal confirmation, clinical, laboratory, and imaging domains contribute to classification. Ayurvedic concepts such as Vata-Rakta interaction and Avarana provide a coherent theoretical explanation of Vatarakta within Ayurveda, but their direct correspondence with specific biomedical mechanisms has not been established. Conclusion: Current evidence does not support treating Vatarakta and gout as universally synonymous. Gout is an important potential modern correlate of Vatarakta, but some presentations may clinically overlap with other arthropathies. A multidomain framework is proposed in which Ayurvedic phenotyping and modern rheumatological assessment are performed independently. Future prospective studies should use standardized Ayurvedic assessment, MSU crystal identification where clinically appropriate, and validated imaging methods to determine which Vatarakta phenotypes correspond to objectively established gout.